thiazoles has been researched along with Dyskinesia Syndromes in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (33.33) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al Keridy, W; Dao, E; Hsiung, GR; Liu-Ambrose, T; Nicklin, E; Shahinfard, E; Sossi, V; Tam, R | 1 |
| Hong, D; Tao, Y; Wu, C; Xu, R; Yang, R; Yang, Y; Yi, J | 1 |
| Barodia, SK; Kumar, JB; Kumari, R; Luthra, PM; Mishra, CB; Prakash, A | 1 |
| Campbell, EC; Caroff, SN; Chakos, MH; Davis, SM; Davis, VG; Keefe, RS; Lieberman, JA; McEvoy, JP; Miller, DD; Riggio, S; Rosenheck, RA; Saltz, BL; Stroup, TS; Swartz, MS | 1 |
| Cheong, HK; Kim, GH; Kim, JS; Kim, SH; Lee, JH; Na, DL; Oh, SJ; Park, HK; Seo, SW | 1 |
| Byrnes, KR; Faden, AI; Loane, DJ; Stoica, BA; Zhang, J | 1 |
| Murray, S; Olié, JP; Spina, E; Yang, R | 1 |
| McIntosh, TK; Perri, BR; Smith, DH; Stutzmann, JM; Voddi, M | 1 |
| Brouillet, E; Guyot, MC; Hantraye, P; Mary, V; Palfi, S; Peschanski, M; Riche, D; Stutzmann, JM; Wahl, F | 1 |
| Gassner, G; Schütt-Mast, I; Stephan, I | 1 |
| Oertel, WH; Pinter, MM; Pogarell, O | 1 |
| Harrigan, EP; Keck, PE; Reeves, KR | 1 |
1 review(s) available for thiazoles and Dyskinesia Syndromes
| Article | Year |
|---|---|
[Observations on the side effects after application of non-steroidal anti-inflammatory agents in dogs].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Dog Diseases; Dogs; Drug Administration Schedule; Female; Gastrointestinal Diseases; Kidney; Male; Meloxicam; Movement Disorders; Thiazines; Thiazoles | 1998 |
5 trial(s) available for thiazoles and Dyskinesia Syndromes
| Article | Year |
|---|---|
Cerebral Amyloid-β Deposition Is Associated with Impaired Gait Speed and Lower Extremity Function.
Topics: Aged; Amyloid beta-Peptides; Aniline Compounds; Brain; Cognitive Dysfunction; Cross-Sectional Studies; Female; Humans; Lower Extremity; Male; Movement Disorders; Muscle Strength; Positron-Emission Tomography; Radiopharmaceuticals; Thiazoles; Walking Speed | 2019 |
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Dibenzothiazepines; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Movement Disorders; Olanzapine; Perphenazine; Piperazines; Proportional Hazards Models; Psychiatric Status Rating Scales; Quetiapine Fumarate; Risperidone; Schizophrenia; Severity of Illness Index; Thiazoles; Treatment Outcome | 2011 |
Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Amisulpride; Antipsychotic Agents; Behavioral Symptoms; Double-Blind Method; Female; Hospitalization; Humans; Ketones; Male; Middle Aged; Movement Disorders; Piperazines; Psychiatric Status Rating Scales; Schizophrenia; Sulpiride; Thiazoles; Time Factors; Treatment Outcome; Weight Gain; Weight Loss | 2006 |
Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.
Topics: Adult; Aged; Antiparkinson Agents; Benzothiazoles; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Pramipexole; Prospective Studies; Thiazoles | 1999 |
Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Movement Disorders; Piperazines; Psychotic Disorders; Thiazoles; Treatment Outcome | 2001 |
6 other study(ies) available for thiazoles and Dyskinesia Syndromes
| Article | Year |
|---|---|
Domoic acid induced spinal cord lesions in adult mice: evidence for the possible molecular pathways of excitatory amino acids in spinal cord lesions.
Topics: Animals; Cell Death; Cell Line, Transformed; Disease Models, Animal; DNA Fragmentation; Dose-Response Relationship, Drug; Female; In Situ Nick-End Labeling; Kainic Acid; Mice; Mice, Inbred C57BL; Movement Disorders; Proteasome Endopeptidase Complex; Reactive Oxygen Species; Severity of Illness Index; Signal Transduction; Spinal Cord Injuries; Tetrazolium Salts; Thiazoles | 2008 |
In silico study of naphtha [1, 2-d] thiazol-2-amine with adenosine A 2A receptor and its role in antagonism of haloperidol-induced motor impairments in mice.
Topics: Adenosine A2 Receptor Antagonists; Animals; Corpus Striatum; Dopamine; Haloperidol; Humans; Male; Mice; Models, Molecular; Motor Activity; Movement Disorders; Naphthalenes; Receptor, Adenosine A2A; Thiazoles; Triazoles | 2009 |
Identification of pure subcortical vascular dementia using 11C-Pittsburgh compound B.
Topics: Aged; Aged, 80 and over; Aniline Compounds; Atrophy; Benzothiazoles; Brain Mapping; Carbon Radioisotopes; Chi-Square Distribution; Dementia, Vascular; Female; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Movement Disorders; Neuropsychological Tests; Positron-Emission Tomography; Psychiatric Status Rating Scales; Temporal Lobe; Thiazoles | 2011 |
Delayed mGluR5 activation limits neuroinflammation and neurodegeneration after traumatic brain injury.
Topics: Animals; Brain Injuries; Calcium-Binding Proteins; Cognition Disorders; Diffusion Tensor Imaging; Disease Models, Animal; Ectodysplasins; Encephalitis; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Glycine; Hippocampus; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred C57BL; Microfilament Proteins; Microglia; Movement Disorders; Neurodegenerative Diseases; Neurons; Phenylacetates; Pyridines; Receptor, Metabotropic Glutamate 5; Receptors, Immunologic; Receptors, Metabotropic Glutamate; Recovery of Function; Statistics, Nonparametric; Thiazoles; Time Factors | 2012 |
Riluzole, a novel neuroprotective agent, attenuates both neurologic motor and cognitive dysfunction following experimental brain injury in the rat.
Topics: Animals; Body Water; Brain Edema; Brain Injuries; Cognition Disorders; Male; Movement Disorders; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Riluzole; Thiazoles | 1996 |
Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration.
Topics: Acetylcholinesterase; Animals; Antiparkinson Agents; Apomorphine; Caudate Nucleus; Corpus Striatum; Movement Disorders; Nerve Degeneration; Neurons; Neuroprotective Agents; Neurotoxins; Nitro Compounds; Papio; Parkinson Disease, Secondary; Propionates; Putamen; Riluzole; Thiazoles | 1997 |